We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Trial in Patients With Psoriasis Treated With Methotrexate Using an Optimized Treatment Schedule (METOP) (METOP)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT02902861
First Posted: September 16, 2016
Last Update Posted: September 16, 2016
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Prof. Kristian Reich, Sciderm GmbH
  Purpose
This is a multicenter, multinational (12 centers planned, in Germany 9 centers and in France, the Netherlands and the United Kingdom (UK) 1 center in each country respectively), randomized, double-blinded, placebo-controlled study. The primary objective is to evaluate the efficacy of methotrexate (MTX) in patients with moderate to severe Psoriasis compared to Placebo as assessed by the primary endpoint "75% reduction of Psoriasis Area Severity Index" (PASI 75 ) during a 16 week treatment phase. As secondary objectives the safety and efficacy of the optimized treatment schedule will be assessed using multiple methods (e.g. (Serious) Adverse Events ((S)AE) occurrence and questionnaires)

Condition Intervention Phase
Psoriasis Vulgaris Drug: Methotrexate Drug: Placebo ( for Methotrexate) Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Official Title: An International Prospective, Double-blind, Placebo-controlled Phase III Randomised Controlled Trial (RCT) in Patients With Moderate to Severe Psoriasis Are Treated With Subcutaneous (s.c.) Methotrexate Using an Optimized Treatment Schedule.

Resource links provided by NLM:


Further study details as provided by Prof. Kristian Reich, Sciderm GmbH:

Primary Outcome Measures:
  • Difference in 75% reduction of Psoriasis Area Severity Index (PASI75) responder rate between treatment arms [ Time Frame: week 16 ]

Secondary Outcome Measures:
  • Difference in PASI75 responder rate between treatment arms [ Time Frame: weeks 52 ]
  • Difference in 50% reduction of Psoriasis Area Severity Index (PASI50) [ Time Frame: weeks 15 and 52 ]
  • Difference in 90% reduction of Psoriasis Area Severity Index (PASI90) [ Time Frame: weeks 15 and 52 ]
  • PASI75 in placebo arm (cross-over) [ Time Frame: weeks 32 ]
  • Difference in Nail Psoriasis Severity Index (NAPSI) [ Time Frame: weeks 16 and 52 ]
  • Difference in Body Surface Area Index (BSA) [ Time Frame: weeks 16 and 52 ]
  • Difference in Physician's Global Assessment (PGA) [ Time Frame: weeks 16 and 52 ]
  • Difference in Psoriatic Arthritis Index (PsA) [ Time Frame: weeks 16 and 52 ]
  • Difference in Patient's satisfaction with metex® pre-filled syringe (PSAT metex®) [ Time Frame: weeks 16 and 52 ]
  • Difference in Dermatology Life Quality Index (DLQI) [ Time Frame: weeks 16 and 52 ]
  • Difference in European Qualification-5D-Questionnaire (EQ-5D) [ Time Frame: weeks 16 and 52 ]
  • Safety and tolerability assessed by Adverse Events (AE)/ Serious Adverse Events (SAE) tolerability at the site of administration [ Time Frame: week 0 - week 51 ]
  • Safety and tolerability assessed by laboratory values [ Time Frame: week 0 - week 51 ]
  • local tolerability at the site of administration assessed by Erythema [ Time Frame: week 0 - week 51 ]

    Erythema (redness): diameter (mm) and severity from none to severe (0 = none,

    1= mild, 2 = moderate 3 = severe)


  • local tolerability at the site of administration assessed by Swelling [ Time Frame: week 0 - week 51 ]

    Swelling/Induration: diameter (mm) and severity from none to severe (0 = none,

    1= mild, 2 = moderate 3 = severe)


  • local tolerability at the site of administration assessed by Hematoma [ Time Frame: week 0 - week 51 ]
    Hematoma: yes/ no and if present diameter (mm)

  • local tolerability at the site of administration assessed by Local Pain [ Time Frame: week 0 - week 51 ]
    Local pain - assessed by the study subject on a visual analogue scale (1-10)

  • local tolerability at the site of administration assessed by Pruritus [ Time Frame: week 0 - week 51 ]
    Pruritus - assessed by the study subject on a visual analogue scale (1-10)

  • Changes of levels of molecular biologic analysis [ Time Frame: at baseline and 16 weeks ]

Enrollment: 120
Study Start Date: February 2013
Study Completion Date: May 2015
Primary Completion Date: September 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: methotrexate
Once weekly (every 7 days) s.c. administration of 17.5 mg MTX. If PASI50 is not reached after 8 weeks (week 8) or PASI75 is not reached after 24 weeks, the dosing will be increased to 22.5 mg MTX/week. If patients were already dosed with 22.5 mg MTX/week in week 24 and PASI50 is not reached, patients will be excluded from treatment. Primary endpoint after 16 weeks.
Drug: Methotrexate
methotrexate 50 mg/ml in syringes for sub-cutaneous injection; Once weekly (every 7 days) s.c. administration of 17.5 mg MTX; If PASI50 is not reached after 8 weeks, the dosing will be increased to 22.5 mg
Other Name: MTX
Placebo Comparator: Placebo (NaCl-Solution)
Once weekly (every 7 days) s.c. administration of 0.35 mL placebo If PASI50 is not reached after 8 weeks (week 8), the dosing will be increased to 0.45 mL placebo/week. Primary endpoint after 16 weeks. After 16 weeks patients will receive 17.5 mg MTX / week. If PASI50 is not reached after 8 weeks of MTX treatment (week 24), uptitration to 22.5 mg MTX/ 0.45 mL Plac / week will be done. Patients, who will reach PASI75 under placebo treatment after 16 weeks, will be dosed neither with placebo nor with MTX until relapse. After relapse the patients will be dosed with a starting dose of 17.5 mg MTX / week.
Drug: Placebo ( for Methotrexate)
NaCl-Solution manufactured to mimic Methotrexate

Detailed Description:
The present study was initiated to further increase the knowledge about the optimal dosing regimen and to thus optimize the efficacy and safety of MTX treatment for patients with moderate to severe psoriasis. In view of the described risk-benefit profile of MTX, an initial dose of at least 15 mg per week administered subcutaneously followed by 5 mg folic acid p.o. 24 hours after MTX application seems appropriate. Since 20 mg MTX per week has been proven to be beneficial in a considerable part of patients, who did not respond sufficiently to 15 mg MTX per week, in this study the dosing starts with a dose of 17.5 mg MTX per week, administered subcutaneously. At such a starting dose, it was expected to find the highest MTX efficacy possible, but with appropriate safety margins. If in a patient, a "50% reduction of Psoriasis Area Severity Index" PASI50 response is not achieved in week 8, the dose will be increased to 22.5 mg MTX per week. All dosages used in this study lay within the approved dosing range of MTX. The study will be conducted in a double-blind, placebo controlled manner. Placebo was chosen as control since only this comparator allows a reliable interpretation of safety and efficacy data.
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Are 18 years of age or older at time of informed consent; may be men or women.
  2. Are MTX naïve
  3. Moderate to severe plaques psoriasis (according rule of ten (PASI ≥10 or BSA ≥ 10 or DLQI ≥ 10) for at least 6 months with or without psoriatic arthritis (however, highly active psoriatic arthritis is excluded, defined by. > 5 swollen tender joints or soles and C-Reactive Protein (CRP) >2 x UNL) .
  4. Women of childbearing potential and all men must be using a highly effective method of contraception (pearl index < 1%) as defined blow and must agree to continue to use such measures and not become pregnant or plan a pregnancy until 6 months after receiving the last injection of Investigational Medicinal Product (IMP).Highly effective method is defined as: Use of oral, injected or implanted hormonal methods, intrauterine device (IUD) or intrauterine system (IUS), barrier methods of contraception: condom or occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/suppository.
  5. Able to adhere to the study visit schedule and other protocol requirements.
  6. Capable of giving informed consent. The informed consent must be obtained prior to any study related procedures.
  7. Must avoid prolonged sun exposure and avoid use of tanning booths or other ultraviolet light sources during study.
  8. Must agree not to receive a live virus or live bacterial vaccination 4 weeks prior to the first IMP s.c. administration, during the trial and up to 3 months after the last injection.
  9. Chest X-ray investigation within the last 6 months prior to first s.c. administration of IMP and show no clinically relevant abnormalities

Exclusion Criteria:

  1. Currently have non-plaque forms of psoriasis (eg, erythrodermic, guttate, or pustular).
  2. Have current drug-induced psoriasis (eg, a new onset of psoriasis or an exacerbation of psoriasis from beta blockers, (hydroxy-) chloroquine, or lithium).
  3. Are pregnant, nursing, or planning pregnancy (both men and women) while enrolled in the study.
  4. Have screening laboratory test results for the following parameters outside the stated ranges (please refer also to :

    1. Hemoglobin < 10 g/dL
    2. White blood cells < 3.0 x 109/L
    3. Neutrophils < 1.5 x 109/L
    4. Platelets < 100 x 109/L
    5. Creatinine clearance (calculated according to Cockcroft-Gault) < 50 mL/min)
    6. Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT), and Gamma Glutamyltransferase (γ-GT) levels must be > 2 times the upper limit of normal range
    7. Bilirubin > 5mg/dl (85,5 μmol/l)
    8. Hypalbuminemia <3,5 g/dl
  5. Have used any other IMP within the previous 4 weeks or 5 times the half-life of an investigational agent prior to the first s.c. administration of the IMP of this study, whichever is longer.
  6. Not able or willing to wash out any prohibited medications as listed below.

    • Any biologics; washout 5 times of half-life
    • Phototherapy or any systemic medications that could affect the psoriasis (including but not limited to oral or injectable corticosteroids, retinoids, 1,25 dihydroxy vitamin D3 and analogues, sulfasalazine, hydroxyurea, or fumaric acid derivates), within 4 weeks
    • Any topical medications that could affect the psoriasis (e.g. corticosteroids, anthralin, calcipotriene, topical vitamin D derivates, retinoids, tazarotene), within 2 weeks
    • Any systemic immunosuppressants (e.g. azathioprine, cyclosporine, 6-thioguanine, mercaptopurine, mycophenolate mofetil, hydroxyurea, and tacrolimus) ,within 4 weeks
    • lithium, antimalarial agents To be stopped directly prior to first s.c. administration of IMP
    • Intramuscular gold ,Within 4 weeks Patients who take prohibited medications that cannot be washed out within 4 weeks or at least 5 times of the half-life of the investigational agent prior to first s.c.

    administration of IMP should not be asked to participate in the trial.

  7. Have a history of chronic or recurrent infectious disease or had a serious infection or have been hospitalized or received i.v. antibiotics for the treatment of an infection within 2 months prior to screening.
  8. History of radiotherapy or planed concomitant radiotherapy
  9. Ulcers of the oral cavity (e.g. ulcerative stomatitis) and/or known gastrointestinal ulcer disease
  10. A known B12/cobalamin deficiency
  11. Known diagnosed ascites or pleural effusions
  12. Have a history of latent or active Tuberculosis (TB) (prior to screening).
  13. Have current signs or symptoms of severe, progressive, or uncontrolled renal (specifically with calculated creatinine clearance < 20), hepatic (especially with bilirubin > 5mg/dl (85,5 mol/l), hematological, gastrointestinal, endocrine, pulmonary, cardiac, neurologic, cerebral, or psychiatric disease.
  14. Have any known malignancy or have a history of malignancy (with the exception of basal cell carcinoma, squamous cell carcinoma in situ of the skin, or cervical carcinoma in situ that has been treated with no evidence of recurrence, or squamous cell carcinoma of the skin that has been treated with no evidence of recurrence within 5 years prior to the first administration of study agent).
  15. Have shown a previous immediate hypersensitivity response, including anaphylaxis, to the folic acid
  16. Are unable or unwilling to undergo multiple venipunctures because of poor tolerability or lack of easy access to veins.
  17. Are known to have had a substance abuse (drug or alcohol) problem within the previous 12 months.
  18. Staff or relatives/partner of any clinical research site
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02902861


Locations
Germany
Psoriasis-Zentrum, Universitäts-Hautklinik Kiel
Kiel, Schleswig-Holstein, Germany, 24105
Sponsors and Collaborators
Prof. Kristian Reich
Investigators
Principal Investigator: Ulrich Mrowietz, Professor Psoriasis-Zentrum, Universitäts-Hautklinik Kiel
  More Information

Responsible Party: Prof. Kristian Reich, Professor, Sciderm GmbH
ClinicalTrials.gov Identifier: NCT02902861     History of Changes
Other Study ID Numbers: 165-001
2012-002716-10 ( EudraCT Number )
First Submitted: July 26, 2016
First Posted: September 16, 2016
Last Update Posted: September 16, 2016
Last Verified: September 2016
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Additional relevant MeSH terms:
Psoriasis
Skin Diseases, Papulosquamous
Skin Diseases
Methotrexate
Abortifacient Agents, Nonsteroidal
Abortifacient Agents
Reproductive Control Agents
Physiological Effects of Drugs
Antimetabolites, Antineoplastic
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Dermatologic Agents
Enzyme Inhibitors
Folic Acid Antagonists
Immunosuppressive Agents
Immunologic Factors
Antirheumatic Agents
Nucleic Acid Synthesis Inhibitors